» Articles » PMID: 26976979

Expression Pattern of CDX2, Estrogen and Progesterone Receptors in Primary Gastroenteropancreatic Neuroendocrine Tumors and Metastases

Overview
Journal Anticancer Res
Specialty Oncology
Date 2016 Mar 16
PMID 26976979
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A significant number of patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs) present with metastatic disease and with unknown primary in about 15% of cases.

Materials And Methods: We analyzed 163 primaries of GEP NET and 115 metastases for expression of caudal type homebox 2 (CDX2), estrogen receptor (ER), progesterone receptor (PR), somatostatin receptor 2a (SSTR2a) and Ki67.

Results: PR was most often positive in pancreatic NET and only rarely in non-pancreatic NET (p<0.001). ER was more frequently expressed in non-pancreatic NET (p<0.001) and was more often positive in females than males (p=0.019). CDX2 was positive in all primaries of the duodenum, ileum and appendix, but was also detected in 24% of metastases with pancreatic primary. SSTR2a and Ki67 did not differ significantly between primaries and metastases.

Conclusion: Our data substantiate the value of PR, ER and CDX2 in GEP NET, and steroid hormone receptors, being differentially expressed in male and female patients. Differences between primaries and metastases were small but potentially relevant.

Citing Articles

Neuroendocrine tumours and pregnancy: Real-world data from an European Neuroendocrine Tumour Centre of Excellence.

Ratnayake G, Shekhda K, Glover T, Al-Obudi Y, Hayes A, Armonis P J Neuroendocrinol. 2024; 37(1):e13465.

PMID: 39503166 PMC: 11750320. DOI: 10.1111/jne.13465.


Association Between Female Sex and Better Survival in Gastroenteropancreatic Neuroendocrine Tumors.

Chang J, Suraju M, Tran C, Chan C, Ear P, Howe J J Surg Res. 2024; 302:53-63.

PMID: 39083906 PMC: 11490409. DOI: 10.1016/j.jss.2024.07.012.


Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases.

Mortagy M, Asmar M, Chandrakumaran K, Ramage J Cancers (Basel). 2024; 16(13).

PMID: 39001438 PMC: 11240657. DOI: 10.3390/cancers16132376.


Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.

Ruggeri R, Aini I, Gay S, Grossrubatscher E, Mancini C, Tarsitano M Rev Endocr Metab Disord. 2023; 25(2):383-398.

PMID: 38051470 DOI: 10.1007/s11154-023-09858-6.


Diagnostic and Prognostic Impact of Progesterone Receptor Immunohistochemistry: A Study Evaluating More Than 16,000 Tumors.

Viehweger F, Tinger L, Dum D, Gorbokon N, Menz A, Uhlig R Anal Cell Pathol (Amst). 2022; 2022:6412148.

PMID: 35992051 PMC: 9381849. DOI: 10.1155/2022/6412148.